Quote
267.35
+0.15 (+0.06%)
We have scored 104 news catalysts on JNJ (JNJ) over the past 12 months. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in sector healthcare and forward growth expectations.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
266.30–268.65
Open
266.81
Prev close
267.20
Volume
3.5M
Avg volume
—
Dividend
—
IPO
—
No scored news tagged JNJ or its network in the window yet.
Show more JNJ articles →Analysts publish price targets on JNJ, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
19 analyst price targets from $260 to $320
as of 2026-09-03
The market is within 2% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about JNJ — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of JNJ, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for JNJ: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The price at $267 sits within 2% of the median published target of $282 and at the 37th percentile of the model spread, meaning the market broadly endorses the consensus but explicitly rejects the 16% upside envisioned by the lone bull case.
What the disagreement turns on
Can Innovative Medicine and MedTech collectively accelerate revenue growth from the delivered 6% toward the 13.1% the price requires, and the available unit volume data can track whether that acceleration is actually happening.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
